| Market Capitalization (Millions $) |
3 |
| Shares
Outstanding (Millions) |
7 |
| Employees |
4 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-3 |
| Cash Flow (TTM) (Millions $) |
4 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Mustang Bio is an innovative biopharmaceutical company that develops new therapies for patients with cancer and rare genetic disorders. The company is focused on developing and commercializing gene therapies that use lentiviral vectors to deliver genes that treat the underlying cause of diseases.
One of the key areas of focus for Mustang Bio is CAR-T (Chimeric Antigen Receptor T-cell) therapy. This innovative approach to treating cancer involves genetically modifying a patient's T-cells to recognize and attack cancer cells. Mustang Bio's CAR-T products are designed to treat a variety of cancers, including acute myeloid leukemia (AML), aggressive B-cell non-Hodgkin lymphoma, and glioblastoma.
Another area of focus for Mustang Bio is gene therapies for rare genetic diseases. These therapies use lentiviral vectors to deliver genes that correct genetic defects, resulting in improved health outcomes for patients. Mustang Bio's lead clinical program in this area is MB-107, a lentiviral vector-based gene therapy for X-linked severe combined immunodeficiency (XSCID), also known as bubble baby syndrome.
Mustang Bio has a strong focus on research and development, with a team of leading scientists and researchers driving the development of new gene therapies. The company also collaborates with leading academic institutions and other biopharmaceutical companies to identify and develop promising therapies.
Founded in 2015, Mustang Bio is headquartered in Worcester, Massachusetts, and has additional offices in New York City and California. The company is led by a seasoned executive team with decades of experience in the biotechnology industry.
Overall, Mustang Bio is a rapidly growing biopharmaceutical company that is focused on developing innovative gene therapies for patients with cancer and rare genetic disorders. With a strong pipeline of products in development and a commitment to advancing the field of gene therapy, Mustang Bio is poised for continued growth and success in the years to come.
Company Address: 95 Sawyer Road, Suite 110 Waltham 2453 MA
Company Phone Number: 652-4500 Stock Exchange / Ticker: NASDAQ MBIO
|
2.95%